Avacopan-based regimen is superior at sustaining remission at Week 52 compared to a GC-based regimen¹

• At Week 26, avacopan-based regimen demonstrated non-inferiority in achieving clinical remission vs a GC-based regimen (p<0.001)
• At Week 52, avacopan-based regimen demonstrated superiority at sustaining clinical remission vs a GC-based regimen (p=0.007)
• Incidences of serious adverse events were similar in avacopan-based regimen and GC-based regimen groups (37.3% vs 39%, respectively)